1 / 2

Therma Bright Inc TSXV THRM OTCQB TBRIF Acquires Patented Technology to Detect Respiratory Diseases

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), is pleased to announce that it has entered a letter of intent (u201cLOIu201d) with AI4LYF LLC (u201cAI4LYFu201d) for the exclusive licensing rights for a digital cough-based diagnosis screening technology. Digital Cough Test (DCT) is a groundbreaking patent-pending technology.

thestreetreports
Download Presentation

Therma Bright Inc TSXV THRM OTCQB TBRIF Acquires Patented Technology to Detect Respiratory Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) Acquires Patented Technology to Detect Respiratory Diseases thestreetreports.com/therma-bright-inc-tsxv-thrm-otcqb-tbrif-acquires-patented-technology-to-detect-respiratory- diseases Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), is pleased to announce that it has entered a letter of intent (“LOI”) with AI4LYF LLC (“AI4LYF”) for the exclusive licensing rights for a digital cough-based diagnosis screening technology. Digital Cough Test (DCT) is a groundbreaking patent-pending technology. Market Action On Thursday, THRM.C stock ended lower by 4.55% to C$0.1050 with more than 312K shares traded hands, compared to its average volume of 459K. 1/2

  2. In the US market, TBRIF stock closed at $0.0800. Therma Bright announced yesterday that it had signed a letter of intent with regards to the acquisition of the exclusive licensing rights to the digital cough-based diagnosis screening technology from the firm AI4LYF LLC. It was a significant new announcement from the company and one that could prove to be a major boost in the long run for Therma Bright. The Digital Cough Test or DCT is a potentially revolutionary artificial intelligence powered technology that had been developed by AI4LYF. It should be noted that the patent for the product is still pending. DCT is something that can detect any respiratory problems in a patient almost instantly and more often than not it is accurate. The respiratory diseases it can detect also include COVID 19. In this regard, it should be noted that the technology is accessed through a smart phone application and an individual can access it anywhere at any time. The technology has been developed in such a way that it can detect the sounds of coughs in an individual in as many as hundreds of ways. It may be a good time for investors to consider keeping an eye on the Therma Bright stock over the coming days. Traders Note THRM.V stock is trading above the 20-Day and 50-Day Moving averages of $0.10 and $0.08 respectively. However, the stock is trading below the 200-Day moving average of $0.16. 2/2

More Related